OGT announced the North American launch of its new next-generation sequencing (NGS) SureSeq Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low frequency measurable residual disease (MRD)-associated biomarkers in acute myeloid leukemia (AML).
This ultra-sensitive NGS panel leverages OGT’s expertise in hybrid capture to enhance the detection of the largest and most complex AML associated variants in key genes, such as large FLT3-ITDs, that often go undetected.
OGT’s new highly targeted SureSeq Myeloid MRD Panel enables the detection of 13 key AML MRD-associated biomarkers. Key targets include very large, ultra-low frequency FLT3-ITDs (even up to 300 bp) that are traditionally challenging to detect. This streamlined, guideline-driven panel content expands on OGT customer’s MRD detection capabilities to deliver a better understanding of the current AML status, and ensures genomic insights are not missed. Customers can also effortlessly adapt NGS workflows to meet all their sensitivity, sample batching and sequencing requirements - by selecting from a range of pre-optimized workflows, users benefit from the unmatched flexibility of this new NGS MRD panel.
